Drug
GSK2190915 100mg
GSK2190915 100mg is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
withdrawn125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
NCT01147744
completedphase_1
A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin
NCT01411111
completedphase_2
GSK2190915 Neutrophilic Asthma Study
NCT01471665
withdrawnphase_1
A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.
NCT01721135
Clinical Trials (4)
Showing 4 of 4 trials
NCT01147744Phase 2
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
NCT01411111Phase 1
A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin
NCT01471665Phase 2
GSK2190915 Neutrophilic Asthma Study
NCT01721135Phase 1
A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4